Daria Kusevich
0000-0002-2976-9724
8 papers found
Refreshing results…
Comparison of the efficacy and safety of the original rituximab and its biosimilar in routine clinical practice
COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance
The role of laboratory biomarkers in monitoring of rituximab biosimilar therapy (Acellbia, “BIOCAD”) in patients with rheumatoid arthritis
Clinical efficacy of the rituximab biosimilar Acellbia® 600 mg in patients with active rheumatoid arthritis in clinical practice
Evaluation of rituximab therapy in real clinical practice (according to the OREL Registry of patients with rheumatoid arthritis),Оценка терапии ритуксимабом в реальной клинической практике (по данным регистра больных ревматоидным артритом ОРЕЛ)
Immunological effects of a rituximab biosimilar (acelbia, biocad) in patients with rheumatoid arthritis
The Efficacy and Safety of Rituximab in Rheumatoid Arthritis: New Evidence
The Role of Laboratory Biomarkers in Predicting the Efficiency of Rituximab Therapy for Rheumatoid Arthritis: New Evidence
Missing publications? Search for publications with a matching author name.